- Home
- ENVB vs NDRA Comparison
ENVB vs NDRA Comparison
Compare ENVB & NDRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENVB
- NDRA
- Stock Information
- Founded
- ENVB 1994
- NDRA 2007
- Country
- ENVB United States
- NDRA United States
- Employees
- ENVB N/A
- NDRA N/A
- Industry
- ENVB Biotechnology: Pharmaceutical Preparations
- NDRA Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- ENVB Health Care
- NDRA Health Care
- Exchange
- ENVB Nasdaq
- NDRA Nasdaq
- Market Cap
- ENVB 3.3M
- NDRA 3.0M
- IPO Year
- ENVB N/A
- NDRA 2017
- Fundamental
- Price
- ENVB $1.36
- NDRA $4.33
- Analyst Decision
- ENVB
- NDRA Strong Buy
- Analyst Count
- ENVB 0
- NDRA 1
- Target Price
- ENVB N/A
- NDRA $14,000.00
- AVG Volume (30 Days)
- ENVB 564.4K
- NDRA 13.9K
- Earning Date
- ENVB 03-25-2025
- NDRA 03-27-2025
- Dividend Yield
- ENVB N/A
- NDRA N/A
- EPS Growth
- ENVB N/A
- NDRA N/A
- EPS
- ENVB N/A
- NDRA N/A
- Revenue
- ENVB N/A
- NDRA N/A
- Revenue This Year
- ENVB N/A
- NDRA N/A
- Revenue Next Year
- ENVB N/A
- NDRA N/A
- P/E Ratio
- ENVB N/A
- NDRA N/A
- Revenue Growth
- ENVB N/A
- NDRA N/A
- 52 Week Low
- ENVB $1.26
- NDRA $4.01
- 52 Week High
- ENVB $657.00
- NDRA $2,170.00
- Technical
- Relative Strength Index (RSI)
- ENVB 16.91
- NDRA 35.49
- Support Level
- ENVB $1.26
- NDRA $4.62
- Resistance Level
- ENVB $1.70
- NDRA $5.40
- Average True Range (ATR)
- ENVB 0.17
- NDRA 0.30
- MACD
- ENVB 2.34
- NDRA -0.05
- Stochastic Oscillator
- ENVB 12.20
- NDRA 0.00
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.
About NDRA ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.